1010-93-1

Basic information

• Product Name: 2-methyl-5-nitroimidazol-1-ylacetic acid
• Synonyms: 2-Methyl-5-nitro-1H-imidazole-1-acetic acid;1H-Imidazole-1-acetic acid, 2-methyl-5-nitro-;Ccris 2147;Metronidazole IMpurity G;1-Carboxymethylmetronidazole;2-(2-Methyl-5-nitro-1H-imidazol-1-yl)acetic acid;2-Methyl-5-nitroimidazole-1-acetic acid;Metronidazole-1-acetic acid
• CAS NO: 1010-93-1
• Molecular Formula: C₆H₇N₃O₄
• Molecular Weight: 185.14
• Mol File: 1010-93-1.mol
• Article Data: 13

Chemical Properties

• Melting Point: 176-178 °C
• Boiling Point: 475.9°Cat760mmHg
• Flash Point: 241.6°C
• Appearance: /
• Density: 1.6g/cm³
• Vapor Pressure: 7.28E-10mmHg at 25°C
• Refractive Index: 1.646
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly, Heated), Methanol (Slightly)
• PKA: 3.65±0.10(Predicted)
• Stability: Hygroscopic
• BRN: 613770
• CAS DataBase Reference: 2-methyl-5-nitroimidazol-1-ylacetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-methyl-5-nitroimidazol-1-ylacetic acid(1010-93-1)
• EPA Substance Registry System: 2-methyl-5-nitroimidazol-1-ylacetic acid(1010-93-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 1010-93-1(Hazardous Substances Data)

Usage

Uses

2-Methyl-5-nitroimidazole-1-acetic Acid is a metabolite of metronidazole with mutagenic activity.

InChI:InChI=1/C6H7N3O4/c1-4-7-2-5(9(12)13)8(4)3-6(10)11/h2H,3H2,1H3,(H,10,11)

Upstream product

• 56910-52-2 2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetaldehyde 
• 443-48-1 metronidazole 
• 1016-40-6 ethyl 2-(2-methyl-5-nitro-1H-imidazole-1-yl)acetate 

Downstream Products

• 1016-40-6 ethyl 2-(2-methyl-5-nitro-1H-imidazole-1-yl)acetate 
• 1214889-81-2 N-[3-(3-fluoro-4-{4-[2-(2-methyl-5-nitro-imidazol-1-yl)-acetyl]-piperazin-1-yl}-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide 
• 1321532-28-8 methyl 3-(4-hydroxyphenyl)-2-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetamido)propanoate 
• 1321532-24-4 ethyl 2-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetamido)-3-phenylpropanoate 
• 1321532-26-6 methyl 2-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetamido)-3-phenylpropanoate 
• 1342253-85-3 2-(2-methyl-5-nitro-1H-imidazol-1-yl)-N-tosylacetamide 
• 1342253-86-4 N-(4-fluorophenylsulfonyl)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetamide 
• 1342253-88-6 N-(4-bromophenylsulfonyl)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetamide 
• 1342253-87-5 N-(4-chlorophenylsulfonyl)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetamide 
• 1342253-84-2 2-(2-methyl-5-nitro-1H-imidazol-1-yl)-N-(phenylsulfonyl)acetamide 

Relevant articles and documents

Design and synthesis of vandetanib derivatives containing nitroimidazole groups as tyrosine kinase inhibitors in normoxia and hypoxia

Sixteen novel epidermal growth factor receptor (EGFR)/vascular endothelial growth factor (VEGF)-2 inhibitors (nitroimidazole-substituted 4-anilinoquinazoline derivatives (16a-p)) were designed and prepared via the introduction of a nitroimidazole group in the piperidine side chain and modification on the aniline moiety of vandetanib. Preliminary biological tests showed that comparing with vandetanib, some target compounds exhibited excellent EGFR inhibitory activities and anti-proliferative over A549/H446 cells in hypoxia. Meanwhile, several of the above compounds demonstrated better bioactivity than vandetanib in VEGF gene expression inhibition. Owing to the excellent IC50 value (1.64 μmol/L), the inhibition ratios of 16f over A549 and H446 cells were 62.01% and 59.86% at the concentration of 0.5 μM in hypoxia, respectively. All of these results indicated that 16f was a potential cancer therapeutic agent in hypoxia and was worthy of further development.

A by the MTZ preparation of amine derivatives furan warm and its preparation and in antibacterial drugs in the application of the

The invention relates to a furanone aniline derivate prepared from metronidazole, as well as a preparation method and applicable of the furanone aniline derivate in antibacterial drugs. The derivant is named as 4-((3,5-dimethoxy phenyl) amino)-3-(2-methyl-5-nitro-1H-iminazol-1-radical)furan-2(5H)-ketone. The derivant represents a better inhibiting and killing effect on to-be-tested bacteria, the inhibiting activity of bacillus subtilis is close to that of positive control kanamycin, and the inhibiting activity of the staphylococcus epidermidis exceeds that of positive control kanamycin, so that the derivant can be used for preparing anti-infective drugs; the influence due to configuration interconversion is improved by replacing the acrylate part of a lead compound with a furan ketone ring, a metronidazole structure with stronger antimicrobial action is introduced, and on the basis of in-depth study of the structure-function relationship, a novel antibacterial derivate with a higher activity is designed and synthesized, and the preparation method of the derivate is provided.

TREATMENTS FOR GASTROINTESTINAL CONDITIONS

Compounds for the treatment of bacterial and parasitic infections which are hybrid compounds of compounds having antibacterial or antiparasitic activity and compounds that decrease the absorption of the hybrid compound from the gastrointestinal tract. The compounds are preferably for use against C. difficile infections and comprise a hybrid molecule of an anti-C. difficile compound such as a nitroimidazole and a tetramic acid derivative.